Stock CLDX CELLDEX THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Celldex Therapeutics, Inc.

Equities

CLDX

US15117B2025

Real-time Estimate Cboe BZX
Other stock markets
 18:57:55 30/04/2024 BST 		5-day change 1st Jan Change
37.69 USD +1.86% Intraday chart for Celldex Therapeutics, Inc. +0.52% -4.27%
04-17 Sector Update: Health Care Stocks Mixed Wednesday Afternoon MT
04-17 Celldex Therapeutics Says Patient Enrollment Completed in Chronic Inducible Urticaria Treatment Study; Shares Rise MT

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • According to Refinitiv, the company's ESG score for its industry is poor.

Strengths

  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
CELLDEX THERAPEUTICS, INC. Stock Celldex Therapeutics, Inc.
-4.27% 2.44B
C-
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+0.48% 42.86B
B
MODERNA, INC. Stock Moderna, Inc.
+12.15% 42.74B
B-
LONZA GROUP AG Stock Lonza Group AG
+44.30% 41.36B
A
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 27.68B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+5.84% 25.15B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-23.64% 18.63B
B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.89% 12.37B
C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.62% 11.92B
C+
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.85% 11.21B
B+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. CLDX Stock
  4. Ratings Celldex Therapeutics, Inc.